Recurrent ovarian cancer: extending platinum-free interval yields poorer survival

  • Dockery LE & al.
  • Gynecol Oncol
  • 12 Sep 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Use of nonplatinum chemotherapy or targeted therapy to prolong platinum-free interval (PFI) is associated with poorer survival in patients with epithelial ovarian cancer (EOC) recurring 6-12 months after primary chemotherapy.

Why this matters

  • Findings highlight the importance of platinum chemotherapy in recurrent EOC.

Study design

  • Study of 177 patients with recurrent EOC and PFI of 6-12 months after primary chemotherapy.
  • PFI1: time from last chemotherapy to date of recurrence.
  • PFS2: time from second-line chemotherapy to initiation of third-line chemotherapy.
  • Funding: None disclosed.

Key results

  • Median PFI1 was 8.2 (95% CI, 8-9) months.
  • 28% of patients did not receive second-line platinum-based chemotherapy.
  • Median PFI1 was significantly longer with platinum-based chemotherapy vs nonplatinum therapy in the second line (8.4 vs 7.6 months; P=.013).
  • Patients received a median of 4.0 treatment lines.
  • Second-line platinum chemotherapy prolonged median PFS2 vs:
    • Nonplatinum therapy: 7.1 vs 3.0 months (P=.0114).
    • Targeted therapy: 7.1 vs 3.0 months (P=.0431).
  • Median OS was longer in patients receiving platinum vs nonplatinum therapy in the second line (43.6 vs 37.6 months; P=.0174).

Limitations

  • Retrospective design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit